[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351996-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351996-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","clinicopathological-characteristics-and-prognostic-analysis-of-synchronous-endometrioid-endometrial-and-ovarian-carcinomas-a-retrospective-cohort-study","Clinicopathological characteristics and prognostic analysis of synchronous endometrioid endometrial and ovarian carcinomas - a retrospective cohort study","","Synchronous endometrioid endometrial and ovarian carcinomas (SEEOCs) are a small but clinically important gynecologic malignancy entity whose clinicopathological correlations, immunohistochemical profiles, and prognosis remain insufficiently defined. A retrospective cohort study evaluated 50 SEEOC cases identified among 1160 endometrioid endometrial carcinoma patients, using immunohistochemistry and Kaplan–Meier analyses to determine progression-free survival predictors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinicopathological-characteristics-and-prognostic-analysis-of-synchronous-endometrioid-endometrial-and-ovarian-carcinomas-a-retrospective-cohort-study/351996/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinicopathological-characteristics-and-prognostic-analysis-of-synchronous-endometrioid-endometrial-and-ovarian-carcinomas-a-retrospective-cohort-study/351996.png","ImageObject",300,407,{"name":42,"@type":43},"Guten tag","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of the study?","Question",{"text":63,"@type":64},"To evaluate clinicopathological characteristics and analyze prognostic factors for synchronous endometrioid endometrial and ovarian carcinomas (SEEOCs).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were prognostic factors assessed?",{"text":68,"@type":64},"Progression-free survival was analyzed using Kaplan–Meier methods, including pairwise comparisons to identify significant factors.",{"name":70,"@type":61,"acceptedAnswer":71},"Which clinical and pathological factors were associated with worse progression-free survival?",{"text":72,"@type":64},"Poor tumor differentiation, >50% myometrial invasion, lymphovascular space invasion, lymph node metastasis, and advanced 2023 FIGO stage were linked to worse PFS.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351996,1790550247,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118,"preview_page_count":33,"preview_urls":145},687212321768,"https://ap-avatar.wpscdn.com/avatar/a0010bdbe886d2fe77?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789897067658708522","Bai etal. BMC Women's Health (2026) 26:358 BMC Women's Health  \n[https://doi.org/10.1186/s12905-026-04559-z](https://doi.org/10.1186/s12905-026-04559-z)  \nRESEARCH Open Access  \nClinicopathological characteristics and prognostic analysis of synchronous endometrioid endometrial and ovarian carcinomas: a retrospective cohort study  \nYanhua Bai1*†, Qi Li2†, Sheng Zhang1†, Wei Wang3, Qian Yao1, Xinqiang Ji4 and Hong Zheng3*  \nAbstract  \nBackground Synchronous endometrioid endometrial and ovarian carcinomas (SEEOCs) represent a small yet clinically significant entity of gynecological malignancies. Their clinicopathological correlations, immunohistochemical profiles, and prognosis have not been well established.  \nMethods We conducted a retrospective analysis of 50 SEEOC cases identified among 1160 patients with endometrioid endometrial carcinoma at a single institution. Clinicopathological parameters, including immunohistochemical profiles, were evaluated. Progression-free survival (PFS) was analyzed, with Kaplan–Meier analysis performed to identify significant prognostic factors.  \nResults Deficient mismatch repair (dMMR) was detected in 36. 1% of SEEOC cases and mutant p53 expression in 13. 2% . PD-L1 (22C3) positivity was observed in 63. 0% cases, and HER2 expression in 75. 0% . Factors associated with worse PFS included poor tumor differentiation, > 50% myometrial invasion, lymphovascular space invasion (LVSI), lymph node metastasis, and advanced 2023 FIGO stage. Kaplan–Meier pairwise comparisons revealed that patients with focal LVSI had a PFS comparable to that of patients with substantial LVSI. Five patients were classified as FIGOIA3 stage. All patients at IA3 stage were premenopausal, showed no MELF (microcystic, elongated, and fragmented) invasion pattern, and none had recurrence.  \nConclusions These findings support the prognostic significance of poor tumor differentiation, > 50% myometrial invasion, LVSI, lymph node metastasis, and 2023 FIGO staging system in SEEOCs. The high rates of dMMR, HER2, and PD-L1 positivity in SEEOCs suggest potential for targeted therapies in future therapeutic strategies.  \nKeywords Synchronous endometrioid endometrial and ovarian carcinomas, Endometrial carcinoma, LVSI, Progression-free survival, FIGO staging  \n†Yanhua Bai, Qi Li and Sheng Zhang contributed equally to this work.  \n*Correspondence:  \nYanhua Bai [byh0425@sina.com](byh0425@sina.com)[ ](byh0425@sina.com)Hong Zheng [zhhong306@hotmail.com](zhhong306@hotmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nBai et al. BMC Women's Health (2026) 26:358  \nIntroduction  \nSynchronous endometrial and ovarian carcinomas occupy a small proportion of gynecological malignancies, with an incidence that varies among different populations, ranging from 3.3% to 10.0% in patients with endomet","cbCaiebSKaPUQnlz","https://ap.wps.com/l/cbCaiebSKaPUQnlz","pdf",1894756,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is the main goal of the study?\",\"answer\":\"To evaluate clinicopathological characteristics and analyze prognostic factors for synchronous endometrioid endometrial and ovarian carcinomas (SEEOCs).\"},{\"question\":\"How were prognostic factors assessed?\",\"answer\":\"Progression-free survival was analyzed using Kaplan–Meier methods, including pairwise comparisons to identify significant factors.\"},{\"question\":\"Which clinical and pathological factors were associated with worse progression-free survival?\",\"answer\":\"Poor tumor differentiation, \\u003e50% myometrial invasion, lymphovascular space invasion, lymph node metastasis, and advanced 2023 FIGO stage were linked to worse PFS.\"}]","Clinicopathological characteristics and prognostic analysis of synchronous endometrioid endometrial and ovarian carcinomas - a retrospective cohort study | PDF",1790096740,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b6affb8244bf9e43ed1151f9b292904.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5183f90b97a969d018a4bcfd57e67300.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a37eda7469d14955709765e3f245887.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e567914b38ca9c14d38318bad94f85fd.webp",980,1306]